Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 5, 2021, DURECT Corporation ("DURECT") announced that the Board of
Directors of DURECT (the "Board"), has appointed, effective as of January 4,
2021 (the "Effective Date"), Ms. Gail Maderis as a Class I director of DURECT
with a term to expire at the 2022 Annual Meeting of Stockholders and Dr.
Mohammed Azab as a Class III director of DURECT with a term to expire at the
2021 Annual Meeting of Stockholders. In connection with the appointments, the
Board approved an increase in the size of the Board, from eight to ten members,
effective as of the Effective Date.
Ms. Gail Maderis, 63 years old, has served as the President, Chief Executive
Officer and a board member of Antiva BioSciences, Inc., a privately held
biopharmaceutical company focused on developing topical therapeutics for
HPV-based diseases, since July 2015. Prior to that, Ms. Maderis served as the
President and Chief Executive Officer of BayBio, an independent, non-profit
trade association serving the life sciences industry in Northern California,
from 2009 until its merger with the California Healthcare Institute in early
2015. From 2003 to 2009, Ms. Maderis was President and Chief Executive Officer
of FivePrime Therapeutics, Inc., a biotechnology company focused on the
discovery and development of innovative protein and antibody drugs, and prior to
that, she held general management positions at Genzyme Corporation, including
Founder and President of Genzyme Molecular Oncology, a publicly traded division
of Genzyme Corporation, and Corporate Vice President of Genzyme Corporation from
1997 to 2003. Ms. Maderis has been a member of several private company boards of
directors, and she previously served as a director of Opexa Therapeutics, Inc.
Ms. Maderis received a B.S. degree in Business Administration from the
University of California at Berkeley and an M.B.A. from Harvard Business School.
The Board believes that Ms. Maderis' operational, industry and leadership
experience in the biopharmaceutical industry as CEO of FivePrime Therapeutics,
Inc., President of Genzyme Molecular Oncology and her current position at
Antiva, and her insight into business and policy trends impacting the biopharma
industry qualify her to serve as a director of DURECT.
Dr. Azab, 65 years old, served as President and Chief Medical Officer of Astex
Pharmaceuticals, Inc., ("Astex"), a pharmaceutical company focused on the
discovery and development of drugs in oncology and other areas from January 2014
to November 2020, and prior to that, he had served as Astex's Chief Medical
Officer from July 2009 to January 2014. Since his retirement, in November 2020,
from his management role, Dr. Azab has served as the Chair of the Board of
Directors for Astex, which is now a wholly owned subsidiary of Otsuka
Pharmaceuticals. Previously, Dr. Azab served as President and CEO of Intradigm
Corporation, a developer of siRNA cancer therapeutics. Prior to this, Dr. Azab
served as Executive Vice President of Research and Development, and Chief
Medical Officer of QLT Inc., and in several leadership positions at Astra Zeneca
in the United Kingdom and Sanofi Pharmaceuticals in France. Dr. Azab holds his
medical degree (MB ChB) from Cairo University and an M.B.A. from the Richard
Ivey School of Business, University of Western Ontario. He received
post-graduate training and degrees in oncology research from the University of
Paris-Sud and biostatistics from the University of Pierre et Marie Curie in
Paris, France. Dr. Azab has more than 30 years of experience in clinical
research, global drug development, and business management and led the global
development of several drugs currently approved in oncology and other
therapeutic areas. He also serves on the board of directors of Xenon
Pharmaceuticals Inc. The Board believes Dr. Azab's scientific background
including his senior management experience in the pharmaceutical industry and as
a board member of a publicly traded company, qualify him to serve on the Board.
Neither Ms. Maderis nor Dr. Azab has any family relationships with any of
DURECT's directors or executive officers and none is a party to any transactions
of the type listed in Item 404(a) of Regulation S-K.
Ms. Maderis and Dr. Azab will each receive cash and equity compensation in
accordance with DURECT's current compensation practices for non-employee
directors. In addition, each will receive a stock option grant at the Company's
2021 annual stockholder meeting in an amount consistent with annual grants
awarded to other non-employee directors and pro-rated to reflecting a partial
year of service prior to the annual meeting. Each will also enter into an
indemnification agreement with DURECT consistent with the form agreement
executed with each of DURECT's current directors.
A copy of the press release announcing these appointments is attached hereto as
Exhibit 99.1.
3
--------------------------------------------------------------------------------
Item 8.01. Other Events.
On January 4, 2021, DURECT announced the closing of the previously disclosed
sale of the Lactel® Absorbable Polymer Product Line to Evonik and receipt of $15
million, effective December 31, 2020. A copy of the press release is attached
hereto as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of DURECT Corporation dated January 5, 20 21
99.2 Press Release of DURECT Corporation dated January 4, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
4
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
DURECT CORPORATION 
